Frontlight ResearchEarly access
TerminatedPhase 2
Proof of Concept Study Evaluating BP1.3656 in Patients With Fatigue Following Ischemic Stroke
Key facts
- Who runs it
- Bioprojet
- Where
- France and Switzerland2 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 5 people enrolled
- Started
- 20 Jan 2023
- Ended
- 8 Feb 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- BP1.3656
- Record updated
- 9 August 2024
- Why it stopped
- Lack of recruitment
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Males or females 18 years old or more
- Diagnosis of ischemic stroke at least one month and not more than six months prior to screening
- Persistent fatigue since the stroke with a score ≥ 50 across all domains of the Multidimensional Fatigue Inventory (MFI-20)
- Modified Rankin Score (mRS) < 3
- Capability to participate in all study tests according to the investigator
- Patient must voluntarily express a willingness to participate in this study, sign and date an informed consent prior to any study specific procedure
- Females of child-bearing potential must have a negative pregnancy test performed at the screening and randomization visits and use a medically accepted effective method of birth control, agree to continue this method for the duration of the study up until three weeks after last treatment intake
Who cannot take part
- History of alcohol or drugs (i.e. cannabis, cocaine, amphetamines or opioids) (ab)use/dependence within the 12 months prior to screening or with a positive drug test at screening
- Any identified etiology for fatigue other than stroke (except post-stroke depression) according to the investigator
- History of psychosis
- Current severe psychiatric disorder, e.g. schizophrenia, bipolar disorder, severe depression, or organic brain syndrome preventing the patients from completing study assessments
- Major cognitive disorders, dementia according to the investigator
- History of epilepsy or seizures disorder
- Glomerular filtration rate <60 mL/min/1.73m² according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
- Other active clinically significant illness, infection, acid-related gastric disorder, or neoplastic pathology within the last 3 years (patients with fully cured non-melanoma skin cancer or in-situ carcinoma of the cervix are eligible) which could interfere with the study conduct or counter-indicate the study treatments or place the patient at risk during the trial or compromise his/her study participation
- Clinically significant cardiovascular abnormalities (including clinically relevant ECG abnormalities) or, clinically significant hematological, neurological, endocrine abnormalities, severe hepatic impairment or Liver Function Tests (ASAT, ALAT) > 3 ULN, or abnormal clinical laboratory results (in most cases > 3ULN)
- Patients at risk of suicide according to the investigator
Where is this trial?
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Multicenter, randomized, double blind, parallel-group, placebo-controlled proof of concept study evaluating efficacy and safety of BP1.3656 in patients with fatigue following ischemic stroke.
The 2 groups in the trial
- BP1.3656Treatment being tested
1 tablet of 30 microgram (µg), 60µg or 90µg of BP1.3656 per day
- PlaceboPlacebo, for comparison
1 tablet of matching placebo per day
Treatment: BP1.3656
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multisite Randomized Clinical Trial Evaluating Efficacy and Safety of BP1.3656 vs Placebo in Patients With Fatigue Following Ischemic Stroke
- Record updated
- 9 August 2024